Health & Medicine
FDA Grants Accelerated Approval for a Head and Neck Cancer Treatment
Rybrevant Faspro is approved for a defined group of adults whose recurrent or metastatic disease progressed after chemotherapy and immunotherapy.
A narrowly defined indication
The Food and Drug Administration granted accelerated approval to Rybrevant Faspro, a combination of amivantamab and hyaluronidase-lpuj, for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed during or after platinum chemotherapy and immunotherapy. The indication excludes HPV-associated oropharyngeal squamous cell carcinoma.
Evidence from an open-label trial
The decision was based on a 102-patient multicenter study. FDA reported an overall response rate of 42 percent, meaning tumors shrank or disappeared under the trial criteria. Among patients who responded, 56 percent had a response lasting at least six months. Response rate is not the same as cure, survival improvement or benefit for every patient.
Why approval is accelerated
The accelerated pathway allows earlier access for serious conditions based on an intermediate measure considered reasonably likely to predict clinical benefit. FDA requires confirmatory studies because long-term clinical benefit has not yet been verified. Continued approval can depend on whether later evidence confirms the expected benefit.
Warnings remain important
The prescribing information includes warnings involving hypersensitivity and administration reactions, lung inflammation, skin reactions, eye toxicity and harm to an unborn baby. Treatment decisions require the full label, patient history and specialist judgment. An approval announcement is not individualized medical advice and should not replace an oncology consultation.
The next evidence
Confirmatory results, safety monitoring and updated labeling will determine the treatment's longer-term place in care. FDA's action provides a new option for a specified population after prior therapies, while leaving important questions open. Patients should confirm that the tumor type, prior treatment and clinical circumstances match the approved indication.
Primary evidence
Reporting note: This independently composed article is based on the linked primary records. Publication and event dates are stated separately. Agency claims are identified as such; an allegation, charge or scheduled event is not presented as a finding, conviction or completed event. Readers should consult the official record for amendments and later action.